natgillin/translations-raw huggingface dataset:
This overview was last updated in June 2019. 
Ta povzetek je bil nazadnje posodobljen junija 2019.
Further information on Advocate can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/advocate. 
Nadaljnje informacije o zdravilu Advocate so na voljo na spletni strani agencije: ema.europa.eu/medicines/veterinary/EPAR/advocate.
Vomiting has also occurred rarely. 
Redko se je pojavilo tudi bruhanje.
Other information about Advocate 
Druge informacije o zdravilu Advocate
The European Medicines Agency decided that Advocate's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila Advocate večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Advocate received a marketing authorisation valid throughout the EU on 2 April 2003. 
Zdravilo Advocate je pridobilo dovoljenje za promet, veljavno po vsej Evropski uniji, 2. aprila 2003.
Advocate should not be used for any other animal species. 
Zdravilo se ne sme uporabljati za nobeno drugo živalsko vrsto.
Dogs and cats weighing less than 1 kg and ferrets weighing less than 0.8 kg should only be treated after special consideration by the veterinarian. 
Psi in mačke, ki tehtajo manj kot 1 kg, ter beli dihurji, ki tehtajo manj kot 0,8 kg, se lahko zdravijo le po posebni presoji veterinarja.
Advocate (imidacloprid / moxidectin) 
Advocate (imidakloprid/moksidektin)
Although no side effects have been confirmed in ferrets, similar side effects could occur rarely. 
Čeprav pri belih dihurjih neželeni učinki niso bili opaženi, se lahko v redkih primerih pojavijo podobni neželeni učinki.
An overview of Advocate and why it is authorised in the EU 
Pregled zdravila Advocate in zakaj je odobreno v EU
People with a known sensitivity to benzyl alcohol, imidacloprid or moxidectin should administer the product with caution. 
Osebe z znano občutljivostjo na benzilalkohol, imidakloprid ali moksidektin naj zdravilo uporabljajo previdno.
Subsequently, the efficacy was confirmed in several field studies in cats and dogs, conducted in different European geographical locations. 
Zatem je bila potrjena v več terenskih študijah z mačkami in psi, izvedenih na različnih geografskih območjih po Evropi.
What are the risks associated with Advocate? 
Kakšna tveganja so povezana z zdravilom Advocate?
Field studies involving heartworm in dogs were conducted both in the USA and Europe. 
Terenske študije, ki so vključevale srčne gliste pri psih, so potekale v ZDA in Evropi.
Advocate should not be used in kittens under 9 weeks of age or in puppies under 7 weeks of age. 
Zdravilo Advocate se ne sme uporabljati pri mačkah, mlajših od devet tednov, ali psih, mlajših od sedem tednov.
When administering Advocate, the user should not smoke, eat or drink, and should wash their hands thoroughly after use. 
Med nanašanjem zdravila Advocate naj uporabnik ne kadi, je ali pije, po uporabi pa naj si temeljito umije roke.
Why is Advocate authorised in the EU? 
Zakaj je bilo zdravilo Advocate odobreno v EU?
What is Advocate and what is it used for? 
Kaj je zdravilo Advocate in za kaj se uporablja?
What benefits of Advocate have been shown in studies? 
Kakšne koristi je zdravilo Advocate izkazalo v študijah?
The effectiveness of the product was measured by the number of live parasites or egg counts in the faeces at various times after treatment. 
Učinkovitost zdravila je bila izmerjena s številom živih zajedavcev ali jajčec v blatu ob različnih časih po zdravljenju.
If a cat or dog licks the application area, it might salivate for a short period and might show signs such as a lack of muscular coordination, shaking, abnormal breathing and/or vomiting. 
Če mačka ali pes poliže mesto nanosa, se utegne kratek čas močno sliniti in kazati znake, kot so pomanjkljiva mišična koordinacija, tresenje, nenormalno dihanje in/ali bruhanje.
It is very important that the cat products should only be used for cats, and the dog products for dogs. 
Zelo pomembno je, da se zdravilo za mačke uporablja le za mačke, zdravilo za pse pa le za pse.
It contains two active substances, imidacloprid and moxidectin. 
Vsebuje dve učinkovini, imidakloprid in moksidektin.
Skin contact with the pipette contents should be avoided and animals should not be stroked or groomed until the application site is dry. 
Preprečiti je treba stik kože z vsebino merilne kapalke, živali pa se ne sme božati ali negovati, dokler se mesto nanosa ne posuši.
The effectiveness of Advocate against the specified parasites was investigated in laboratory studies in cats, ferrets and dogs. 
Učinkovitost zdravila Advocate proti navedenim zajedavcem je bila proučena z laboratorijskimi študijami pri mačkah, belih dihurjih in psih.
The results of the laboratory and field trials in cats, ferrets and dogs showed that Advocate is effective, when used as detailed in the package leaflet (see “What is Advocate and what is it used for?” above, or for more details see the package leaflet). 
Rezultati laboratorijskih in terenskih preskušanj na mačkah, belih dihurjih in psih so pokazali, da je zdravilo Advocate učinkovito, če se uporablja v skladu z navodilom za uporabo (glej razdelek „Kaj je zdravilo Advocate in za kaj se uporablja?“ zgoraj, za več podrobnosti pa navodilo za uporabo).
Moxidectin causes paralysis and death of parasites by interfering with the way signals are passed between nerve cells (neurotransmission) in the parasites' nervous system. 
Moksidektin povzroči ohromitev in pogin zajedavcev tako, da ovira prenos signalov med živčnimi celicami (živčni prenos) v njihovem živčevju.
Imidacloprid interferes with certain specific receptors (nicotinergic acetylcholine receptors) in the nervous systems of lice and fleas, which results in their subsequent paralysis and death. 
Imidakloprid ovira nekatere posebne receptorje (nikotinske acetilholinske receptorje) v živčnem sistemu uši in bolh, kar povzroči njihovo ohromitev in pogin.
The content of a full pipette is applied onto the animal's skin, after parting the fur. 
Vsebina celotne merilne kapalke se nanese na kožo živali po razmiku dlake.
The solvent in Advocate may stain or damage certain materials including leather, fabrics, plastics and finished surfaces, so contact between the product and such surfaces should be avoided. 
Vehikel v zdravilu Advocate lahko pusti madeže na nekaterih materialih, kot so usnje, tkanine, plastika in lakirane površine, oziroma jih poškoduje, zato je treba preprečiti stik zdravila s tovrstnimi površinami.
In both cats and dogs, the most common side effects are local reactions at the site of application, such as temporary itchiness, and on rare occasions, greasy fur and redness of the skin. 
Pri mačkah in psih so najpogostejši neželeni učinki lokalne reakcije na mestu nanosa zdravila, kot so začasno srbenje ter v redkih primerih mastna dlaka in pordelost kože.
Advocate is a medicine used on cats, ferrets and dogs suffering from, or at risk from, mixed parasitic infections (caused by several different types of parasites): 
Zdravilo Advocate se uporablja pri mačkah, belih dihurjih in psih, ki imajo mešane parazitske okužbe (ki jih povzročajo različne vrste zajedavcev) ali pri katerih obstaja tveganje zanje:
Advocate should not be used in dogs classified as Class 4 for heartworm disease. 
Uporabljati se ne sme niti pri psih, ki so razvrščeni v razred 4 obolenja, ki ga povzroča srčna glista.
How is Advocate used? 
Kako se zdravilo Advocate uporablja?
Advocate is available as a spot-on solution in pre-filled pipettes (small plastic droppers), and comes in different strengths and pack sizes, depending on whether it is for use on cats, ferrets, or dogs, and on the size of the animal being treated. 
Zdravilo Advocate je na voljo kot raztopina za kožni nanos v napolnjeni merilni kapalki (majhni plastični kapalki), in sicer v različnih jakostih in pakiranjih glede na to, ali je namenjeno za uporabo pri mačkah, belih dihurjih ali psih, ter glede na velikost zdravljene živali.
• as part of treatment strategies for flea allergy dermatitis (an allergic reaction to flea bites) in cats and dogs; 
• kot del strategije zdravljenja alergijskega dermatitisa, ki ga povzročajo bolhe (alergijske reakcije na ugrize bolh) pri mačkah in psih;
Cats, ferrets and dogs from various breeds, age groups and weights were treated. 
Zdravljeni so bili psi, beli dihurji in mačke različnih pasem, starosti in telesnih mas.
• for the treatment of skin diseases in dogs caused by parasitic mites (sarcoptic mange and demodicosis); 
• za zdravljenje kožnih bolezni, ki jih povzročajo parazitske pršice (garje vrste Sarcoptes in demodikoze) pri psih;
Only the product called “Advocate spot-on solution for small cats and ferrets” should be used for ferrets. 
imenovano Advocate raztopina za kožni nanos za majhne mačke in bele dihurje (Advocate Spot-on solution for Small Cats and Ferrets).
• for the treatment of infections with certain gastrointestinal roundworms, hookworms and whipworms in cats and dogs. 
• za zdravljenje okužb z nekaterimi želodčno-črevesnimi glistami, trakuljami in bičeglavci pri mačkah in psih.
Advocate comes in different strengths and different pipette sizes depending on whether it is for use on cats, ferrets or dogs. 
Zdravilo je na voljo v različnih jakostih in v merilnih kapalkah različnih velikosti glede na to, ali se uporablja za zdravljenje mačk, belih dihurjev ali psov.
• for the prevention and treatment of skin worm (infection with Dirofilaria repens) in dogs; 
• za preprečevanje in zdravljenje kožnih glist (okužba z glistami Dirofilaria repens) pri psih;
• for the prevention of spirocercosis (a worm infection affecting the gullet) in dogs; 
• za preprečevanje spirocerkoze (okužbe z zajedavci, ki prizadene požiralnik) pri psih;
• for the prevention of heartworm disease (infection with Dirofilaria immitis) in cats, ferrets and dogs; 
• za preprečevanje obolenj, ki jih povzročajo srčne gliste (okužba z glistami Dirofilaria immitis) pri mačkah, belih dihurjih in psih;
• for the prevention and treatment of lungworm in cats and dogs; 
• za preprečevanje in zdravljenje okužb s pljučnimi glistami pri mačkah in psih;
• for the treatment and prevention of flea infestations in cats, ferrets and dogs; 
• za zdravljenje in preprečevanje infestacij z bolhami pri mačkah, belih dihurjih in psih;
How does Advocate work? 
Kako zdravilo Advocate deluje?
The dose and frequency of application depend on why Advocate is being used and whether it is used in cats, ferrets or dogs; the package leaflet includes detailed information on dosage and duration of treatment. 
Odmerek in pogostost nanosa sta odvisna od razloga za uporabo zdravila Advocate in od tega, ali se uporablja pri mačkah, belih dihurjih ali psih.
• for the treatment of ear mite infestations in cats and dogs; 
• za zdravljenje ušesnih garij pri mačkah in psih;
• for the treatment of eye worm in cats and dogs; 
• za zdravljenje očesnih zajedavcev pri mačkah in psih;
• for the treatment of nasal worm in dogs; 
• za zdravljenje nosnih zajedavcev pri psih;
• for the treatment of notoedric mange in cats; 
• za zdravljenje garjavosti, ki jo povzročajo pršice vrste Notoedres, pri mačkah;
• for the treatment of biting lice infestations in dogs; 
• za zdravljenje ušivosti pri psih;
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 16 December 1998 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve odobritve: 16. december 1998 Datum zadnjega podaljšanja: 16. december 2008
It is important that you take Kinzalmono every day until your doctor tells you otherwise. 
Pomembno je, da jemljete zdravilo Kinzalmono vsak dan, dokler vam zdravnik ne naroči drugače.
See also information under the heading “Do not take Kinzalmono”. 
Glejte tudi informacije pod naslovom “Ne jemljite zdravila Kinzalmono”.
Aluminium/aluminium blisters (PA/PA/Al/PVC/Al). 
Pretisni omoti iz aluminija/aluminija (PA/Al/PVC/Al ali PA/PA/Al/PVC/Al).
Some side effects can be serious and need immediate medical attention You should see your doctor immediately if you experience any of the following symptoms: 
Nekateri neželeni učinki so lahko resni in zahtevajo takojšnjo zdravstveno oskrbo Nemudoma morate obiskati zdravnika, če se pojavi kateri od naslednjih simptomov:
One blister contains 7 tablets. 
En pretisni omot vsebuje 7 tablet.
What Kinzalmono is and what it is used for 
Kaj je zdravilo Kinzalmono in za kaj ga uporabljamo
This applies especially to the medicines listed below taken at the same time with Kinzalmono: 
To velja zlasti za spodaj našteta zdravila, kadar jih jemljete hkrati z zdravilom Kinzalmono:
Your doctor will normally advise you to stop taking Kinzalmono before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Kinzalmono. 
Zdravnik vam bo praviloma svetoval, da zdravilo Kinzalmono prenehate jemati, preden boste zanosili ali takoj ko boste vedeli, da ste noseči, in vam svetoval, da namesto zdravila Kinzalmono jemljete drugo zdravilo.
4.5 Interaction with other medicinal products and other forms of interaction 
4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Digoksin
If you take more Kinzalmono than you should If you accidentally take too many tablets, contact your doctor, pharmacist, or your nearest hospital emergency department immediately. 
Če ste vzeli večji odmerek zdravila Kinzalmono, kot bi smeli Če pomotoma vzamete preveč tablet, morate nemudoma poklicati svojega zdravnika, farmacevta ali oddelek za nujno pomoč v najbližji bolnišnici.
• If you are taking an ACE-inhibitor or aliskiren (see also information under the headings “Do not take Kinzalmono” and “Warnings and precautions”). 
• zaviralec ACE ali aliskiren (glejte tudi informacije pod naslovoma "Ne jemljite zdravila Kinzalmono" in "Opozorila in previdnostni ukrepi"),
If you forget to take Kinzalmono 
Če ste pozabili vzeti zdravilo Kinzalmono
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) 
Neželeni učinki so razvrščeni glede na pogostnost po naslednjih kriterijih: zelo pogosti ( 1/10); pogosti ( 1/100 do < 1/10); občasni ( 1/1.000 do < 1/100); redki ( 1/10.000 do < 1/1.000); zelo redki (< 1/10.000).
Other medicines and Kinzalmono 
Druga zdravila in zdravilo Kinzalmono
There are no adequate data from the use of Kinzalmono in pregnant women. 
Ni zadostnih podatkov o uporabi zdravila Kinzalmono pri nosečnicah.
Some people feel dizzy or tired when taking Kinzalmono. 
Nekateri ljudje so med zdravljenjem z zdravilom Kinzalmono omotični ali utrujeni.
Children and adolescents The use of Kinzalmono in children and adolescents up to the age of 18 years is not recommended. 
Otroci in mladostniki Uporabe zdravila Kinzalmono pri otrocih in mladostnikih do 18. leta starosti ne priporočamo.
Patients with rare hereditary problems of fructose intolerance should not take Kinzalmono. 
Bolniki z redko dedno intoleranco za fruktozo ne smejo jemati zdravila Kinzalmono.
What you need to know before you take Kinzalmono 
Kaj morate vedeti, preden boste vzeli zdravilo Kinzalmono
You should consult with your doctor if you need to adjust the dose of your other medicine while taking Kinzalmono. 
Z zdravnikom se morate posvetovati, ali je treba med jemanjem zdravila Kinzalmono prilagoditi odmerek vašega drugega zdravila.
Kinzalmono is used to treat essential hypertension (high blood pressure) in adults. 
Zdravilo Kinzalmono uporabljamo za zdravljenje esencialne hipertenzije (visokega krvnega tlaka) pri odraslih.
If you have the impression that the effect of Kinzalmono is too strong or too weak, talk to your doctor or pharmacist. 
Če menite, da je učinek zdravila Kinzalmono premočan ali prešibak, se posvetujte z zdravnikom ali s farmacevtom.
What Kinzalmono is and what it is used for What you need to know before you take Kinzalmono How to take Kinzalmono 
Kaj je zdravilo Kinzalmono in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Kinzalmono Kako jemati zdravilo Kinzalmono Možni neželeni učinki
Do not take Kinzalmono 
Ne jemljite zdravila Kinzalmono
In preclinical studies, no effects of Kinzalmono on male and female fertility were observed. 
V predkliničnih študijah niso zasledili učinkov zdravila Kinzalmono na plodnost moških in žensk.
The safety and efficacy of Kinzalmono in children and adolescents aged below 18 years have not been established. 
Varnost in učinkovitost zdravila Kinzalmono pri otrocih in mladostnikih, mlajših od 18 let, še nista bili dokazani.
Remove your Kinzalmono tablet from the blister only directly prior to intake. 
Tableto zdravila Kinzalmono vzemite iz pretisnega omota tik, preden jo boste zaužili.
Kinzalmono contains sorbitol. 
Zdravilo Kinzalmono vsebuje sorbitol.
The main risk factors for hyperkalaemia to be considered are: - Diabetes mellitus, renal impairment, age (>70 years) - Combination with one or more other medicinal products that affect the renin-angiotensinaldosterone system and/or potassium supplements. 
Glavni dejavniki tveganja za pojav hiperkaliemije, ki jih je treba upoštevati, so: - sladkorna bolezen, ledvična okvara, starost (>70 let); - kombinacija z enim ali več drugimi zdravili, ki učinkujejo na renin-angiotenzin-aldosteronski sistem, ali s kalijevimi nadomestki.
The tablets should be swallowed with some water or other non-alcoholic drink. 
Zdravilo Kinzalmono lahko jemljete s hrano ali ne. Tablete morate pogoltniti z nekaj vode ali druge brezalkoholne pijače.
In case of surgery or anaesthesia, you should tell your doctor that you are taking Kinzalmono. 
Če boste operirani ali boste prejeli anestezijo, morate vašemu zdravniku povedati, da jemljete zdravilo Kinzalmono.
Talk to your doctor before taking Kinzalmono if you are suffering or have ever suffered from any of the following conditions or illnesses: 
Pred začetkom jemanja zdravila Kinzalmono se posvetujte z zdravnikom, če imate ali ste kadar koli v preteklosti imeli katero od naslednjih stanj ali bolezni:
If you are intolerant to some sugars, consult your doctor before taking Kinzalmono. 
Če ne prenašate nekaterih sladkorjev, se posvetujte s svojim zdravnikom, preden vzamete zdravilo Kinzalmono.
The effect of Kinzalmono may be reduced when you take NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen) or corticosteroids. 
Učinek zdravila Kinzalmono se lahko zmanjša, če jemljete nesteroidna protivnetna zdravila (na primer aspirin ali ibuprofen) ali kortikosteroide.
• Low blood pressure (hypotension), likely to occur if you are dehydrated (excessive loss of body water) or have salt deficiency due to diuretic therapy ('water tablets'), low-salt diet, diarrhoea, 
• nizek krvni tlak (hipotenzijo), ki se lahko pojavi, če ste dehidrirani (prevelika izguba vode iz telesa) ali imate pomanjkanje soli zaradi diuretičnega zdravljenja (tablet za odvajanje vode),
Telmisartan tablets are for once-daily oral administration and should be taken with liquid with or without food. 
Telmisartan tablete se jemljejo peroralno enkrat na dan s tekočino, s hrano ali brez nje.
Kinzalmono is contraindicated in patients with severe hepatic impairment (see section 4.3). 
Zdravilo Kinzalmono je kontraindicirano pri bolnikih s hudo jetrno okvaro (glejte poglavje 4.3).
The concomitant use of Kinzalmono with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5, and 5.1). 
Sočasna uporaba zdravila Kinzalmono in zdravil, ki vsebujejo aliskiren je kontraindicirana pri bolnikih s sladkorno boleznijo ali z okvaro ledvic (hitrost glomerularne filtracije < 60 ml/min/1,73 m2) (glejte poglavji 4.5 in 5.1).
Kinzalmono may increase the blood pressure lowering effect of other medicines used to treat high blood pressure or of medicines with blood pressure lowering potential (e.g. baclofen, amifostine). 
Zdravilo Kinzalmono lahko poveča učinek znižanja krvnega tlaka drugih zdravil za zdravljenje visokega krvnega tlaka, ali zdravil z možnim antihipertenzivnim učinkom (npr. baklofen, amifostin).
Kinzalmono is also used to reduce cardiovascular events (i.e. heart attack or stroke) in adults who are at risk because they have a reduced or blocked blood supply to the heart or legs, or have had a stroke or have high risk diabetes. 
Zdravilo Kinzalmono uporabljamo tudi za zmanjševanje srčnožilnih dogodkov (npr. srčnega napada ali možganske kapi) pri odraslih z velikim tveganjem zaradi zmanjšane ali blokirane oskrbe srca ali nog s krvjo, ali pri odraslih, ki so doživeli možgansko kap ali imajo sladkorno bolezen z velikim tveganjem.
14 tablets 28 tablets 56 tablets 98 tablets 28 x 1 tablets 
14 tablet 28 tablet 56 tablet 98 tablet 28 x 1 tableta
Kinzalmono belongs to a class of medicines known as angiotensin II receptor antagonists. 
Zdravilo Kinzalmono sodi v skupino zdravil, ki jih imenujemo antagonisti angiotenzina II.
Kinzalmono may be less effective in lowering the blood pressure in black patients. 
Zdravilo Kinzalmono lahko pri črni rasi manj učinkovito znižuje krvni tlak.
Kinzalmono is not to be given to patients with cholestasis, biliary obstructive disorders or severe hepatic impairment (see section 4.3) since telmisartan is mostly eliminated with the bile. 
Zdravila Kinzalmono se ne daje bolnikom, ki imajo holestazo, obolenja z zaporo žolčevoda ali hudo jetrno okvaro (glejte poglavje 4.3), ker se telmisartan pretežno izloča z žolčem.
As with other medicinal products acting on the renin-angiotensin-aldosterone-system, telmisartan may provoke hyperkalaemia (see section 4.4). 
Telmisartan lahko tako kot druga zdravila, ki delujejo na renin-angiotenzin-aldosteronski sistem, povzroči hiperkaliemijo (glejte poglavje 4.4).
When Kinzalmono is used in patients with impaired renal function, periodic monitoring of potassium and creatinine serum levels is recommended. 
Kadar bolnike z ledvično okvaro zdravimo z zdravilom Kinzalmono, moramo periodično nadzorovati serumski ravni kalija in kreatinina.
Kinzalmono is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section). 
Uporaba zdravila Kinzalmono ni priporočljiva v zgodnjem obdobju nosečnosti in ga ne smete jemati, če ste noseči več kot 3 mesece, ker lahko v tem obdobju resno škoduje vašemu otroku (glejte poglavje o nosečnosti).
When driving vehicles or operating machinery it should be taken into account that dizziness or drowsiness may occasionally occur when taking antihypertensive therapy such as Kinzalmono. 
Bolniki, ki vozijo motorna vozila ali upravljajo stroje, morajo upoštevati, da lahko antihipertenzivno zdravljenje, na primer z zdravilom Kinzalmono, včasih povzroči omotico ali dremavost.
If any of the above applies to you, tell your doctor or pharmacist before taking Kinzalmono. 
Če imate karkoli od naštetega, povejte zdravniku ali farmacevtu, preden boste vzeli zdravilo Kinzalmono.
Because no information is available regarding the use of Kinzalmono during breast-feeding, Kinzalmono is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant. 
Ker o uporabi telmisartana med dojenjem ni podatkov, ga ne priporočajo, zato je treba med dojenjem, še zlasti med dojenjem novorojenčkov ali prezgodaj rojenih dojenčkov, dajati prednost alternativnim zdravilom, katerih varnostne lastnosti so bolj raziskane.
Kinzalmono blocks the effect of angiotensin II so that the blood vessels relax, and your blood pressure is lowered. 
Zdravilo Kinzalmono zavira učinek angiotenzina II in tako sprosti krvne žile, zato se vam krvni tlak zniža.